COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals aged 12 years and above.
The virus-like particle (VLP) single-dose vaccine is the first chikungunya vaccine to receive approval in Switzerland and was approved following review of the regulatory dossier submitted in July 2025, upon the FDA and EMA approvals of the vaccine earlier in 2025.
“The Swiss approval marks another important milestone in our endeavors to bring protection against chikungunya to more people and reinforces our commitment to expanding access to our vaccine globally,” said Paul Chaplin, President & CEO of Bavarian Nordic.
The approval of VIMKUNYA in Switzerland marks the fourth approval of Bavarian Nordic’s chikungunya vaccine, which was approved by the U.S. Food and Drug Administration (FDA), the European Commission and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2025. Bavarian Nordic has also submitted an application to Health Canada, potentially supporting approval of the chikungunya vaccine in the first half of 2026.
About VIMKUNYA® Chikungunya vaccine (recombinant, adsorbed)
VIMKUNYA is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination.
The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination.
About chikungunya
Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas,
